Alizadeh Zeinabad Hojjat, Szegezdi Eva
Apoptosis Research Centre, Biomedical Sciences Building, School of Biological and Chemical Sciences, University of Galway, H91 W2TY Galway, Ireland.
Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM), Biomedical Sciences Building, University of Galway, H91 W2TY Galway, Ireland.
Cancers (Basel). 2022 Oct 19;14(20):5125. doi: 10.3390/cancers14205125.
The death ligand tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF cytokine superfamily, has long been recognized for its potential as a cancer therapeutic due to its low toxicity against normal cells. However, its translation into a therapeutic molecule has not been successful to date, due to its short in vivo half-life associated with insufficient tumor accumulation and resistance of tumor cells to TRAIL-induced killing. Nanotechnology has the capacity to offer solutions to these limitations. This review provides a perspective and a critical assessment of the most promising approaches to realize TRAIL's potential as an anticancer therapeutic, including the development of fusion constructs, encapsulation, nanoparticle functionalization and tumor-targeting, and discusses the current challenges and future perspectives.
死亡配体肿瘤坏死因子（TNF）相关凋亡诱导配体（TRAIL）是TNF细胞因子超家族的成员，长期以来因其对正常细胞毒性低而被认为具有作为癌症治疗药物的潜力。然而，由于其体内半衰期短，导致肿瘤蓄积不足以及肿瘤细胞对TRAIL诱导的杀伤具有抗性，迄今为止，将其转化为治疗分子尚未成功。纳米技术有能力为这些局限性提供解决方案。本文综述提供了一个视角，并对实现TRAIL作为抗癌治疗药物潜力的最有前景的方法进行了批判性评估，包括融合构建体的开发、封装、纳米颗粒功能化和肿瘤靶向，并讨论了当前的挑战和未来前景。
